Cargando…
State-of-the-art of minimally invasive treatments of bone metastases
Bone metastases is a common manifestation of advanced malignant tumors. With the recent advances in medical technology, the survival period of patients with malignant tumors is prolonged, and the probability of bone metastases is significantly increased. Approximately 70% to 80% of patients with bre...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980625/ https://www.ncbi.nlm.nih.gov/pubmed/35391944 http://dx.doi.org/10.1016/j.jbo.2022.100425 |
_version_ | 1784681431967989760 |
---|---|
author | Li, Cun Wu, Qianghua Chang, Daijun Liang, Hui Ding, Xiaofei Lao, Chendeng Huang, Zonggui |
author_facet | Li, Cun Wu, Qianghua Chang, Daijun Liang, Hui Ding, Xiaofei Lao, Chendeng Huang, Zonggui |
author_sort | Li, Cun |
collection | PubMed |
description | Bone metastases is a common manifestation of advanced malignant tumors. With the recent advances in medical technology, the survival period of patients with malignant tumors is prolonged, and the probability of bone metastases is significantly increased. Approximately 70% to 80% of patients with breast or prostate cancer will eventually develop bone metastases. In addition, thyroid, lung, and kidney carcinomas are all known to cause bone metastases, with a 30% to 40% incidence upon postmortem assessment. Bone metastases often lead to severe pain, pathological fractures, and nerve damage and have become a critical factor affecting the quality of life and life expectancy of cancer patients. Although treatments for bone metastases are diverse, choosing the appropriate treatment is difficult. Both conservative treatment and open surgery have certain drawbacks and may not be appropriate for all patients. Interventional procedures have the advantages of less trauma with quicker recovery and represent a viable alternative. This review provides updates on the progress of research on the interventional treatment of bone metastases and directions regarding relevant further studies. |
format | Online Article Text |
id | pubmed-8980625 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-89806252022-04-06 State-of-the-art of minimally invasive treatments of bone metastases Li, Cun Wu, Qianghua Chang, Daijun Liang, Hui Ding, Xiaofei Lao, Chendeng Huang, Zonggui J Bone Oncol Review Article Bone metastases is a common manifestation of advanced malignant tumors. With the recent advances in medical technology, the survival period of patients with malignant tumors is prolonged, and the probability of bone metastases is significantly increased. Approximately 70% to 80% of patients with breast or prostate cancer will eventually develop bone metastases. In addition, thyroid, lung, and kidney carcinomas are all known to cause bone metastases, with a 30% to 40% incidence upon postmortem assessment. Bone metastases often lead to severe pain, pathological fractures, and nerve damage and have become a critical factor affecting the quality of life and life expectancy of cancer patients. Although treatments for bone metastases are diverse, choosing the appropriate treatment is difficult. Both conservative treatment and open surgery have certain drawbacks and may not be appropriate for all patients. Interventional procedures have the advantages of less trauma with quicker recovery and represent a viable alternative. This review provides updates on the progress of research on the interventional treatment of bone metastases and directions regarding relevant further studies. Elsevier 2022-03-19 /pmc/articles/PMC8980625/ /pubmed/35391944 http://dx.doi.org/10.1016/j.jbo.2022.100425 Text en © 2022 Published by Elsevier GmbH. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Article Li, Cun Wu, Qianghua Chang, Daijun Liang, Hui Ding, Xiaofei Lao, Chendeng Huang, Zonggui State-of-the-art of minimally invasive treatments of bone metastases |
title | State-of-the-art of minimally invasive treatments of bone metastases |
title_full | State-of-the-art of minimally invasive treatments of bone metastases |
title_fullStr | State-of-the-art of minimally invasive treatments of bone metastases |
title_full_unstemmed | State-of-the-art of minimally invasive treatments of bone metastases |
title_short | State-of-the-art of minimally invasive treatments of bone metastases |
title_sort | state-of-the-art of minimally invasive treatments of bone metastases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980625/ https://www.ncbi.nlm.nih.gov/pubmed/35391944 http://dx.doi.org/10.1016/j.jbo.2022.100425 |
work_keys_str_mv | AT licun stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT wuqianghua stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT changdaijun stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT lianghui stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT dingxiaofei stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT laochendeng stateoftheartofminimallyinvasivetreatmentsofbonemetastases AT huangzonggui stateoftheartofminimallyinvasivetreatmentsofbonemetastases |